[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvVNkzLxM4KtYo3K72PUnIbHPZQxF--Psq6cVzIk7IBg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":50,"rows":57},"National Heart Centre Singapore",[4],62,false,20,0,7342897,5,56,[14,17,20,22,24,27,30,32],{"name":15,"count":16},"Coronary Artery Disease",11,{"name":18,"count":19},"Cardiovascular Diseases",6,{"name":21,"count":19},"Heart Failure",{"name":23,"count":11},"Ischemic Heart Disease",{"name":25,"count":26},"Hypertension",4,{"name":28,"count":29},"Diabetes Mellitus",3,{"name":31,"count":29},"Cardiac Ageing",{"name":33,"count":29},"Coronary Stenosis",[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04286399","Asian Diabetes Outcomes Prevention Trial","2022-06-30","Renin-angiotensin-aldosterone system inhibitors",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05912218","REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD","2025-09-01","MEI6570",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06645691","Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body","2028-05-31","Hyperpolarized 13C-pyruvate",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,83,101,119,143,166,191,217,243],{"intervention":39,"totalTrials":59,"cells":60},1,{"EARLY_PHASE1":61,"PHASE1":63,"PHASE2":65,"PHASE3":67,"PHASE4":69,"NA":81},{"trials":62,"activeCount":9},[],{"trials":64,"activeCount":9},[],{"trials":66,"activeCount":9},[],{"trials":68,"activeCount":9},[],{"trials":70,"activeCount":59,"soonestReadout":38},[71],{"nctId":36,"briefTitle":37,"status":72,"phases":73,"primaryCompletion":38,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":78},"RECRUITING",[55],"2034-06-30","2019-07-01",2400,[28,18],[39,79,80],"Beta blocker","SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product",{"trials":82,"activeCount":9},[],{"intervention":79,"totalTrials":59,"cells":84},{"EARLY_PHASE1":85,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":93,"NA":99},{"trials":86,"activeCount":9},[],{"trials":88,"activeCount":9},[],{"trials":90,"activeCount":9},[],{"trials":92,"activeCount":9},[],{"trials":94,"activeCount":59,"soonestReadout":38},[95],{"nctId":36,"briefTitle":37,"status":72,"phases":96,"primaryCompletion":38,"completion":74,"start":75,"enrollment":76,"conditions":97,"interventions":98},[55],[28,18],[39,79,80],{"trials":100,"activeCount":9},[],{"intervention":80,"totalTrials":59,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":117},{"trials":104,"activeCount":9},[],{"trials":106,"activeCount":9},[],{"trials":108,"activeCount":9},[],{"trials":110,"activeCount":9},[],{"trials":112,"activeCount":59,"soonestReadout":38},[113],{"nctId":36,"briefTitle":37,"status":72,"phases":114,"primaryCompletion":38,"completion":74,"start":75,"enrollment":76,"conditions":115,"interventions":116},[55],[28,18],[39,79,80],{"trials":118,"activeCount":9},[],{"intervention":44,"totalTrials":59,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":137,"PHASE4":139,"NA":141},{"trials":122,"activeCount":9},[],{"trials":124,"activeCount":9},[],{"trials":126,"activeCount":59,"soonestReadout":43},[127],{"nctId":41,"briefTitle":42,"status":128,"phases":129,"primaryCompletion":43,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":136},"ACTIVE_NOT_RECRUITING",[53],"2025-12-01","2023-11-02",70,[134,135],"Diabetes Mellitus, Type 2","Peripheral Arterial Disease",[44],{"trials":138,"activeCount":9},[],{"trials":140,"activeCount":9},[],{"trials":142,"activeCount":9},[],{"intervention":49,"totalTrials":59,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":160,"PHASE4":162,"NA":164},{"trials":146,"activeCount":9},[],{"trials":148,"activeCount":9},[],{"trials":150,"activeCount":59,"soonestReadout":48},[151],{"nctId":46,"briefTitle":47,"status":72,"phases":152,"primaryCompletion":48,"completion":48,"start":153,"enrollment":154,"conditions":155,"interventions":159},[53],"2024-10-17",200,[21,156,157,18,158],"Cardiometabolic Syndrome","Cancer Diagnosis","Healthy Volunteers",[49],{"trials":161,"activeCount":9},[],{"trials":163,"activeCount":9},[],{"trials":165,"activeCount":9},[],{"intervention":167,"totalTrials":59,"cells":168},"Dapagliflozin 10 MG [Forxiga]",{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":189},{"trials":170,"activeCount":9},[],{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":9},[179],{"nctId":180,"briefTitle":181,"status":182,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT04080518","Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment","COMPLETED",[55],"2021-11-10","2019-11-11",40,[28,21],[167],{"trials":190,"activeCount":9},[],{"intervention":192,"totalTrials":59,"cells":193},"Cangrelor",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":195,"activeCount":9},[],{"trials":197,"activeCount":9},[],{"trials":199,"activeCount":9},[200],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT03102723","Platelet Inhibition to Target Reperfusion Injury","UNKNOWN",[53],"2022-12","2017-10-01",228,[209],"STEMI",[192],{"trials":212,"activeCount":9},[],{"trials":214,"activeCount":9},[],{"trials":216,"activeCount":9},[],{"intervention":218,"totalTrials":59,"cells":219},"Entresto",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":221,"activeCount":9},[],{"trials":223,"activeCount":9},[],{"trials":225,"activeCount":9},[226],{"nctId":227,"briefTitle":228,"status":182,"phases":229,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT03553810","Role of ARNi in Ventricular Remodeling in Hypertensive LVH",[53],"2024-06-28","2019-04-12",80,[234],"Hypertensive Heart Disease",[218,236],"Valsartan",{"trials":238,"activeCount":9},[],{"trials":240,"activeCount":9},[],{"trials":242,"activeCount":9},[],{"intervention":236,"totalTrials":59,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":255,"PHASE4":257,"NA":259},{"trials":246,"activeCount":9},[],{"trials":248,"activeCount":9},[],{"trials":250,"activeCount":9},[251],{"nctId":227,"briefTitle":228,"status":182,"phases":252,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":253,"interventions":254},[53],[234],[218,236],{"trials":256,"activeCount":9},[],{"trials":258,"activeCount":9},[],{"trials":260,"activeCount":9},[]]